Publication

In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes

European Journal of Pharmacology 815:181–189, 2017

Skarbaliene J, Rigbolt KT, Fosgerau K, Billestrup N

View publication

Share this page

Resource Library

Related resources

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice

Imaging diabetes using light sheet microscopy

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650